Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

Share Price is delayed by 15 minutes
Get Live Data
26.40    0.00 (0.00%)
Bid:
26.10
Ask:
27.40
Spread: 1.30 (4.981%)
Market Cap: £113.65m
EKF Live PriceLast checked at - London Stock Exchange

Intraday Ekf Diagnostics Share Chart

Update

20 Mar 2017 07:00

RNS Number : 8764Z
EKF Diagnostics Holdings PLC
20 March 2017
 

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).

 

EKF Diagnostics Holdings plc

("EKF", the "Company")

 

Update

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces the following update for shareholders.

 

The Directors are currently evaluating plans under which they would split the Company into two separate companies based on the business divisions, namely Point of Care and Lab Diagnostics. Whilst both these business divisions are valuable in their own right, the Directors consider that separating the companies out represents a better route for shareholders and one under which they are more likely to achieve a fair reflection of the value of each separate business.

 

However, based on tax advice received by the Company, it is the Directors' understanding that US federal income tax chargeable on any gain associated with the divestiture of the business could be significant. In order to mitigate these potentially adverse tax effects, the distribution needs to qualify as a 'tax-free spinoff'. There are numerous requirements in order to achieve this treatment, including that no acquisition of 50% or more of the shares in either the Company (i.e. the business that remains following the divestiture) or the newly separated company may take place within two years of the separation. Accordingly, the articles of association of the two separate companies would be amended so as to include a prohibition of the sale of 50% or more of the shares in the companies without the consent of their directors.

 

The implementation of the above proposal is envisaged to include a cancellation of the Company's shares from trading on AIM following which it is the Directors current intention to seek a listing of the shares of both companies on a market to be determined.

 

The Directors are sympathetic to individual investors' requirements and therefore in order to provide those shareholders that do not wish to wait for the completion of the restructuring and subsequent potential sale of the two businesses with an exit, the Company is evaluating the possibility of a share buyback offer to shareholders. This share buyback offer would, if completed, be prior to the commencement of the separation and would be at a price of 21.5p per share.

 

There can of course be no guarantee that the above proposals, including any share buyback, will be capable of being completed in the manner currently anticipated. Further announcements will be made at the appropriate time

 

 

EKF Diagnostics Holdings plc

www.ekfdiagnostics.com

Christopher Mills, Non-Executive Chairman

Tel: 029 2071 0570

Julian Baines, CEO 

Richard Evans, FD & COO

N+1 Singer (Nomad & Broker)

Tel: 020 7496 3000

Alex Price / Shaun Dobson

Walbrook PR Limited

Tel: 020 7933 8780 or ekf@walbrookpr.com

Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
UPDGCGDXRXBBGRC
Date   Source Headline
13th Jan 20097:00 amRNSRe Joint Venture
16th Dec 200810:18 amPRNChange of Adviser
24th Nov 20084:07 pmPRNHolding(s) in Company
25th Sep 20087:00 amPRNSale of Japan Trademarks
7th Aug 20084:20 pmPRNHolding(s) in Company
4th Aug 20087:00 amPRNHalf-yearly Report
7th Jul 20087:00 amPRNSale of Southern Africa Trademarks
24th Jun 20087:00 amPRNSale of Turkey Trademarks
23rd Jun 20087:00 amPRNFinal Results
21st Dec 20071:58 pmPRNHolding(s) in Company
20th Dec 20077:00 amPRNAdmiral Licence Agreement in China
3rd Dec 20077:00 amPRNSale of Eastern Europe Trademark
19th Sep 20077:00 amPRNHalf-yearly Report
17th Aug 20075:02 pmPRNAIM Rule 26 Compliance
25th Jun 20074:27 pmPRNCorrection: Holdings in Company
25th Jun 20072:54 pmPRNHoldings in Company
20th Jun 20074:00 pmPRNHolding in Company
18th Jun 200712:21 pmPRNResult of AGM
15th Jun 20077:00 amPRNNew License Agreement
3rd May 20077:00 amPRNPreliminary Results
30th Apr 20077:00 amPRNNew Agreement with Gulf Region
25th Apr 20073:00 pmPRNChange of Registered Office
19th Apr 20074:23 pmPRNHolding in Company
18th Apr 200711:00 amPRNIBL Assigns England Cricket Contract
17th Apr 20079:44 amPRNHolding in Company
28th Mar 20075:42 pmPRNHolding in Company
22nd Mar 20079:55 amPRNHolding in Company
19th Mar 20074:41 pmPRNHolding in Company
20th Feb 20079:38 amPRNHolding(s) in Company
20th Dec 200612:02 pmPRNTotal Voting Rights
9th Nov 20069:53 amPRNHolding(s) in Company
8th Nov 20067:00 amPRNNew Admiral License Agreement for the USA
27th Oct 20067:00 amPRNNew Admiral Team License
24th Oct 20067:15 amPRNAGREEMENT WITH RAJAN GROUP
24th Oct 20067:00 amPRNNEW AGREEMENT WITH ASDA
17th Oct 20067:00 amPRNAcquisition of Muscle Athletic Sports Brand
19th Sep 20067:00 amPRNIBL
11th Sep 20067:00 amPRNInterim Results 2006
11th Sep 20067:00 amPRNInterim Results 2006
4th Jul 20067:00 amPRNAgreement with New Licensee
29th Jun 20067:00 amPRNCompletion of Admiral Greek License Sale
20th Jun 20067:00 amPRNAgreement with New Licensee
15th May 200610:26 amPRNAGM Statement
10th May 20067:00 amPRNSale of Greek License
3rd May 20067:00 amPRNCancellation of Options
20th Apr 20063:41 pmPRNDirector/PDMR Shareholding
20th Apr 20067:00 amPRNGrant of Options
19th Apr 20067:00 amPRNFinal Results
7th Mar 20067:00 amPRNChange of Adviser
20th Feb 20067:00 amPRNHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.